Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice

Circulation. 2004 Nov 9;110(19):3062-7. doi: 10.1161/01.CIR.0000137970.47771.AF. Epub 2004 Jul 26.

Abstract

Background: Angiotensin II type 1 (AT1) receptor activation is potentially involved in the multifactorial pathogenesis of atherosclerosis.

Methods and results: Apolipoprotein E-deficient (ApoE-/-) mice were crossed with AT1A receptor-deficient (AT1-/-) mice to obtain homozygous double-knockout animals (ApoE-/--AT1-/- mice). Wild-type (C57BL/6J), ApoE-/-, AT1-/-, and ApoE-/--AT1-/- mice were fed a high-cholesterol diet for 7 weeks. In contrast to wild-type and AT1-/- mice, this treatment led to severe atherosclerotic lesion formation in the aortic sinus and the aorta (oil red O staining) and to an impaired endothelium-dependent vasodilation (organ chamber experiments with isolated aortic segments) in ApoE-/- mice. In the age-matched ApoE-/--AT1-/- littermates, development of diet-induced endothelial dysfunction and atherosclerotic lesion formation was profoundly inhibited. Concomitantly, aortic release of superoxide radicals was increased 2-fold in ApoE-/- mice compared with wild-type animals, whereas aortic superoxide production was normalized in ApoE-/--AT1-/- mice (L-012 chemiluminescence). There were no significant differences in plasma cholesterol levels between ApoE-/- and ApoE-/--AT1-/- animals. Systolic blood pressure was significantly lower in ApoE-/--AT1-/- animals than in ApoE-/- mice (tail-cuff measurements). Oral treatment of ApoE-/- mice with either hydralazine or irbesartan reduced systolic blood pressure to the same level; however, only AT1 receptor antagonist treatment reduced atherosclerotic lesion formation and improved endothelial function.

Conclusions: Genetic disruption of the AT1A receptor leads to inhibition of vascular oxidative stress, endothelial dysfunction, and atherosclerotic lesion formation in ApoE-/- mice irrespective of blood pressure and plasma cholesterol levels. These results indicate a fundamental role of AT1 receptor activation in atherogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Animals
  • Aortic Diseases / etiology
  • Aortic Diseases / genetics
  • Aortic Diseases / physiopathology
  • Aortic Diseases / prevention & control
  • Apolipoproteins E / deficiency*
  • Apolipoproteins E / genetics
  • Apolipoproteins E / physiology
  • Arteriosclerosis / drug therapy
  • Arteriosclerosis / etiology
  • Arteriosclerosis / genetics
  • Arteriosclerosis / physiopathology
  • Arteriosclerosis / prevention & control*
  • Biphenyl Compounds / therapeutic use
  • Cholesterol, Dietary / toxicity
  • Diet, Atherogenic
  • Genetic Predisposition to Disease
  • Hemodynamics
  • Hydralazine / therapeutic use
  • Hyperlipoproteinemia Type II / complications*
  • Hyperlipoproteinemia Type II / genetics
  • Irbesartan
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Receptor, Angiotensin, Type 1 / deficiency*
  • Receptor, Angiotensin, Type 1 / genetics
  • Receptor, Angiotensin, Type 1 / physiology
  • Renin / blood
  • Superoxides / metabolism
  • Tetrazoles / therapeutic use
  • Vasoconstriction / drug effects

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Apolipoproteins E
  • Biphenyl Compounds
  • Cholesterol, Dietary
  • Receptor, Angiotensin, Type 1
  • Tetrazoles
  • Superoxides
  • Hydralazine
  • Renin
  • Irbesartan